July 5, 2018
Will Pfizer Japan’s next-generation ALK inhibitor lorlatinib qualify for the price maintenance premium (PMP) scheme for innovative medicines? The drug might bag the country’s first conditional drug approval as early as this autumn, but its fourth-in-class status in the ALK...read more